Quick Answer
SANGAMO THERAPEUTICS, INC reported Diluted EPS of $0.44 per share (loss) for fiscal year 2025.
SANGAMO THERAPEUTICS, INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.44 | +10.2% |
| 2024 | -$0.49 | +66.9% |
| 2023 | -$1.48 | -18.4% |
| 2022 | -$1.25 | -1.6% |
| 2021 | -$1.23 | -36.7% |
| 2020 | -$0.90 | -5.9% |
| 2019 | -$0.85 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.11 | -375.0% | -37.5% |
| June 30, 2025 | -$0.08 | +55.6% | +42.9% |
| March 31, 2025 | -$0.14 | +48.1% | -450.0% |
| September 30, 2024 | $0.04 | +106.8% | +122.2% |
| June 30, 2024 | -$0.18 | +72.7% | +33.3% |
| March 31, 2024 | -$0.27 | -325.0% | +54.2% |
| September 30, 2023 | -$0.59 | -73.5% | +10.6% |
| June 30, 2023 | -$0.66 | -127.6% | -650.0% |
- SANGAMO THERAPEUTICS, INC showed an increase of +10.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, SANGAMO THERAPEUTICS, INC’s diluted eps has grown by 48.2% (from $0.85 per share (loss) to $0.44 per share (loss)).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: